Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Trastuzumab Deruxtecan (DS-8201a) kontra wybór badacza w leczeniu raka piersi z niskim HER2, który się rozprzestrzenił lub którego nie można usunąć chirurgicznie [DESTINY-Breast04]

1 września 2026 zaktualizowane przez: Daiichi Sankyo

Faza 3, wieloośrodkowe, randomizowane, otwarte badanie z aktywną kontrolą DS-8201a, koniugatu przeciwciała anty-HER2-lek (ADC), w porównaniu z leczeniem z wyboru lekarza dla pacjentów z niskim HER2, nieoperacyjnym i/lub przerzutowym rakiem piersi

This study will compare DS-8201a to physician choice standard treatment.

Participants must have HER2-low breast cancer that has been treated before.

Participants' cancer:

  • Cannot be removed by an operation
  • Has spread to other parts of the body

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.

The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

557

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Innsbruck, Austria, 6020
        • Medizinische Universität Innsbruck
      • Linz, Austria, 4020
        • Kepler Universitätsklinikum
      • Salzburg, Austria, 5020
        • LKH - Universitätsklinikum der PMU Salzburg
      • Vienna, Austria, 1090
        • AKH - Medizinische Universität Wien (4305)
      • Wels, Austria, 4600
        • Klinikum Wels-Grieskirchen GmbH
      • Brussels, Belgia, 1000
        • Institut Jules Bordet
      • Brussels, Belgia, 1090
        • Universitair Ziekenhuis Brussel
      • Brussels, Belgia, 1200
        • Cliniques Universitaires Saint-Luc
      • Leuven, Belgia, 3000
        • UZ Leuven
      • Loverval, Belgia, 6280
        • Grand Hôpital de Charleroi
      • Namur, Belgia, 5000
        • CHU UCL Namur
      • Tournai, Belgia, 7500
        • Centre Hospitalier Wallonie picarde - Site IMC
    • Anhui
      • Hefei, Anhui, Chiny, 230001
        • Anhui Provincial Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chiny, 100853
        • Chinese PLA General Hospital
      • Beijing, Beijing Municipality, Chiny, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
    • Fujian
      • Fuzhou, Fujian, Chiny, 350025
        • Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
    • Guangdong
      • Guangzhou, Guangdong, Chiny, 510120
        • Sun Yat-sen Memorial hospital, Sun Yat-sen University
    • Heilongjiang
      • Harbin, Heilongjiang, Chiny, 150081
        • Harbin Medical University Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Chiny, 430079
        • Hubei Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Chiny, 210008
        • The Affiliated Drum Tower Hospital of Nanjing University
    • Jilin
      • Changchun, Jilin, Chiny, 130000
        • The First Hospital of Jilin University
      • Changchun, Jilin, Chiny, 130012
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, Chiny, 110042
        • Liaoning Cancer Hospital & Institute
    • Ningxia Hui
      • Yinchuan, Ningxia Hui, Chiny, 750004
        • General Hospital of Ningxia Medical University
    • Shandong
      • Linyi, Shandong, Chiny, 276001
        • Linyi Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chiny, 200080
        • Shanghai General Hospital
      • Shanghai, Shanghai Municipality, Chiny, 20032
        • Fudan University Shanghai Cancer Center
    • Sichuan
      • Chengdu, Sichuan, Chiny, 610041
        • West China Hospital, Sichuan University
    • Zhejiang
      • Hangzhou, Zhejiang, Chiny, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, Chiny, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
      • Paris, Francja, 75020
        • Hopital Tenon
      • Paris, Francja, 75005
        • Institut Curie - site de Paris
    • Bouches-du-Rhône
      • Marseille, Bouches-du-Rhône, Francja, 13009
        • Institut Paoli Calmettes
    • Calvados
      • Caen, Calvados, Francja, 14076
        • Centre François Baclesse
    • Cotes d'Armor
      • Plérin, Cotes d'Armor, Francja, 22190
        • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    • Finistere
      • Brest, Finistere, Francja, 29609
        • CHU Brest - Hôpital Morvan
    • Gironde
      • Bordeaux, Gironde, Francja, 33076
        • Institut Bergonié
    • Herault
      • Montpellier, Herault, Francja, 34070
        • Clinique Clementville
      • Montpellier, Herault, Francja, 34298
        • Institut Régional du Cancer de Montpellier
    • Ille Et Vilaine
      • Rennes, Ille Et Vilaine, Francja, 35042
        • CRLCC Eugene Marquis
    • Loire Atlantique
      • Saint-Herblain, Loire Atlantique, Francja, 44805
        • ICO - Site René Gauducheau
    • Loiret
      • Le Puy-en-Velay, Loiret, Francja, 43012
        • Centre Hospitalier Emile Roux
    • Maine Et Loire
      • Angers, Maine Et Loire, Francja, 49055
        • ICO - Site Paul Papin
    • Nord
      • Valenciennes, Nord, Francja, 59322
        • Centre Hospitalier Valenciennes
    • Paris
      • Paris, Paris, Francja, 75475
        • Hôpital Saint-Louis - Paris
    • Sarthe
      • Le Mans, Sarthe, Francja, 72015
        • Clinique Victor Hugo - Centre Jean Bernard
    • Vaculuse
      • Avignon, Vaculuse, Francja, 84918
        • Institut Sainte Catherine
    • Val De Marne
      • Saint-Mandé, Val De Marne, Francja, 94160
        • Hôpital d'Instruction des Armees Begin*
      • Villejuif, Val De Marne, Francja, 94805
        • Institut Gustave Roussy
      • Athens, Grecja, 15125
        • Athens Medical Center
      • Athens, Grecja, 11528
        • General Hospital of Athens "Alexandra"
      • Athens, Grecja, 14564
        • General Oncology Hospital of Kifissia " Agioi Anargyroi"
      • Heraklion, Grecja, 71110
        • University General Hospital of Heraklion
      • Larissa, Grecja, 41110
        • University General Hospital of Larissa
      • Thessaloniki, Grecja, 54622
        • Bioclinic Thessaloniki
      • Thessaloniki, Grecja, 54645
        • Euromedica General Clinic Thessaloniki
      • Thessaloniki, Grecja, 56429
        • General Hospital Papageorgiou
      • Thessaloniki, Grecja, 57001
        • Interbalkan Hospital of Thessaloniki
      • Barcelona, Hiszpania, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Hiszpania, 08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Hiszpania, 08023
        • Hospital Quironsalud Barcelona
      • Barcelona, Hiszpania, 08003
        • Hospital del Mar
      • Madrid, Hiszpania, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Hiszpania, 28040
        • Hospital Universitario Clinico San Carlos
      • Madrid, Hiszpania, 28034
        • Hospital Ruber Internacional
      • Madrid, Hiszpania, 28033
        • MD Anderson Cancer Centre
      • Málaga, Hiszpania, 29010
        • Hospital Clinico Universitario Virgen de la Victoria
      • Seville, Hiszpania, 41009
        • Hospital Universitario Virgen Macarena
      • Seville, Hiszpania, 41013
        • Hospital Universitario Virgen del Rocio
      • Valencia, Hiszpania, 46014
        • Hospital General Universitario de Valencia
      • Valencia, Hiszpania, 46009
        • Instituto Valenciano de Oncologia IVO
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Hiszpania, 08908
        • ICO l'Hospitalet - Hospital Duran i Reynals
    • Guipuzcoa
      • San Sebastián, Guipuzcoa, Hiszpania, 20014
        • Hospital Universitario Donostia
    • La Coruña
      • A Coruña, La Coruña, Hiszpania, 15006
        • Complejo Hospitalario Universitario A Coruña
    • Tenerife
      • San Cristóbal de La Laguna, Tenerife, Hiszpania, 38320
        • Hospital Universitario de Canarias
    • Vizcaya
      • Bilbao, Vizcaya, Hiszpania, 48013
        • Hospital de Basurto
      • Haifa, Izrael, 3109601
        • Rambam Health Care Center
      • Jerusalem, Izrael, 9103102
        • Shaare Zedek Medical Center
      • Jerusalem, Izrael, 9112001
        • Hadassah University Hospital - Ein Kerem
      • Petah Tikva, Izrael, 49100
        • Rabin Medical Center-Beilinson Campus
      • Ramat Gan, Izrael, 52363
        • Chaim Sheba Medical Center
      • Rehovot, Izrael, 7610001
        • Kaplan Medical Center
      • Safed, Izrael, 13100
        • Ziv Medical Center
      • Tel Aviv, Izrael, 6423906
        • Tel Aviv Sourasky Medical Center
    • Aichi-ken
      • Nagoya, Aichi-ken, Japonia, 464-8681
        • Aichi Cancer Center Hospital
    • Chiba
      • Kashiwa-shi, Chiba, Japonia, 277-8577
        • National Cancer Center Hospital East
    • Ehime
      • Matsuyama, Ehime, Japonia, 791-0280
        • NHO Shikoku Cancer Center
    • Fukuoka
      • Fukuoka, Fukuoka, Japonia, 811-1395
        • NHO Kyushu Cancer Center
    • Fukushima
      • Fukushima, Fukushima, Japonia, 960-1295
        • Fukushima Medical University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Japonia, 730-8518
        • Hiroshima City Hiroshima Citizens Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japonia, 003-0804
        • NHO Hokkaido Cancer Center
    • Hyōgo
      • Nishinomiya-shi, Hyōgo, Japonia, 663-8501
        • Hyogo College of Medicine Hospital
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japonia, 892-0833
        • Hakuaikai Sagara Hospital
    • Kanagawa
      • Isehara, Kanagawa, Japonia, 259-1193
        • Tokai University Hospital
      • Yokohama, Kanagawa, Japonia, 241-8515
        • Kanagawa Cancer Center
    • Osaka
      • Osaka, Osaka, Japonia, 540-0006
        • NHO Osaka National Hospital
    • Osakasayama-shi
      • Onohigashi, Osakasayama-shi, Japonia, 589-8511
        • Kindai University Hospital
    • Saitama
      • Kitaadachi-gun, Saitama, Japonia, 362-0806
        • Saitama Cancer Center
    • Shizuoka
      • Sunto-gun, Shizuoka, Japonia, 411-8777
        • Shizuoka Cancer Center
    • Tokyo-To
      • Kōtoku, Tokyo-To, Japonia, 135-8550
        • Cancer Institute Hospital of JFCR
      • Minatoku, Tokyo-To, Japonia, 105-8470
        • Toranomon Hospital
      • Shinagawa-Ku, Tokyo-To, Japonia, 142-8666
        • Showa University Hospital
    • Alberta
      • Calgary, Alberta, Kanada, T2N4N2
        • Tom Baker Cancer Center
    • Ontario
      • Toronto, Ontario, Kanada, M4N 3M5
        • Toronto Sunnybrook Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H2W 1S6
        • McGill University - Dept. Oncology Clinical Research Program
      • Daegu, Korea Południowa, 41404
        • Kyungpook National University Chilgok Hospital
      • Seoul, Korea Południowa, 03080
        • Seoul National University Hospital
      • Seoul, Korea Południowa, 05505
        • Asan Medical Center
      • Seoul, Korea Południowa, 06351
        • Samsung Medical Center
      • Seoul, Korea Południowa, 06591
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul, Korea Południowa, 120-752
        • Severance Hospital, Yonsei University Health System
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Korea Południowa, 10408
        • National Cancer Center
      • Incheon, Gyeonggi-do, Korea Południowa, 22332
        • Inha University Hospital
      • Seongnam-si, Gyeonggi-do, Korea Południowa, 13620
        • Seoul National University Bundang Hospital
      • Suwon, Gyeonggi-do, Korea Południowa, 16499
        • Ajou University Hospital
    • North Chungcheong
      • Cheongju-si, North Chungcheong, Korea Południowa, 361-711
        • Chungbuk National University Hospital
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Niemcy, 69120
        • Universitaetsklinikum Heidelberg
    • Bavaria
      • Munich, Bavaria, Niemcy, 81377
        • Klinikum der Universitaet Muenchen - Campus Grosshardern
      • Braga, Portugalia, 4710-243
        • Hospital de Braga
      • Guimarães, Portugalia, 4835-044
        • Centro Hospitalar do Alto do Ave, EPE
      • Lisbon, Portugalia, 1649-035
        • Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
      • Lisbon, Portugalia, 1400-038
        • Fundação Champalimaud
      • Matosinhos Municipality, Portugalia, 4464-509
        • Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
      • Porto, Portugalia, 4200-072
        • Instituto Português de Oncologia do Porto Francisco Gentil, EPE
      • Porto, Portugalia, 4099-001
        • Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
      • Santa Maria da Feira, Portugalia, 4520-211
        • Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
      • Vila Nova de Gaia, Portugalia, 4434-502
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
      • Vila Real, Portugalia, 5000-508
        • Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
      • Moscow, Rosja, 115478
        • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
      • Moscow, Rosja, 143423
        • SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
      • Yaroslavl, Rosja, 150054
        • SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
    • Arizona
      • Chandler, Arizona, Stany Zjednoczone, 85224
        • Ironwood Cancer & Research Centers - Chandler II
      • Gilbert, Arizona, Stany Zjednoczone, 85234
        • Banner MD Anderson Cancer Center
      • Goodyear, Arizona, Stany Zjednoczone, 85338
        • Cancer Treatment Centers of America at Western Regional Medical Center
    • California
      • Los Angeles, California, Stany Zjednoczone, 90095
        • UCLA School of Medicine
      • Palo Alto, California, Stany Zjednoczone, 94305
        • Stanford Cancer Institute
      • Redondo Beach, California, Stany Zjednoczone, 90277
        • Cancer Care Associates Medical Group, Inc. TORI
      • San Francisco, California, Stany Zjednoczone, 94158
        • University of California at San Francisco (PARENT)
    • Connecticut
      • Norwich, Connecticut, Stany Zjednoczone, 06360
        • Eastern Connecticut Hematology/Oncology Assoc.
    • Delaware
      • Newark, Delaware, Stany Zjednoczone, 19713
        • Christiana Care Health Services, Inc.
    • Florida
      • Boca Raton, Florida, Stany Zjednoczone, 33426
        • Sylvester Comprehensive Cancer Center - Deerfield Beach
      • Fort Myers, Florida, Stany Zjednoczone, 33916
        • Florida Cancer Specialists (South Region)
      • Hollywood, Florida, Stany Zjednoczone, 33021
        • Memorial Healthcare System MRH Cancer Center
      • Orlando, Florida, Stany Zjednoczone, 32806
        • Orlando Health, Inc.
      • Tampa, Florida, Stany Zjednoczone, 33139
        • Moffitt Cancer Center -Tampa
    • Georgia
      • Newnan, Georgia, Stany Zjednoczone, 30263
        • Cancer Treatment Centers of America-Georgia
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60637
        • University of Chicago Medical Center
      • Zion, Illinois, Stany Zjednoczone, 60099
        • Cancer Treatment Centers of America
    • Kansas
      • Wichita, Kansas, Stany Zjednoczone, 67214
        • Cancer Center of Kansas
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70115
        • Touro Infirmary
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, Stany Zjednoczone, 48202
        • Henry Ford Hospital
    • Missouri
      • Kansas City, Missouri, Stany Zjednoczone, 64111
        • Saint Luke's Hospital of Kansas City
    • New Jersey
      • Livingston, New Jersey, Stany Zjednoczone, 07039
        • Saint Barnabas Medical Center
    • New York
      • New York, New York, Stany Zjednoczone, 10016
        • New York University Medical Center
      • New York, New York, Stany Zjednoczone, 10065
        • Memorial Sloan Kettering Hospital
      • New York, New York, Stany Zjednoczone, 10065
        • Weill Cornell Medicine Breast Center
    • Ohio
      • Cleveland, Ohio, Stany Zjednoczone, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15212
        • Allegheny General Hospital
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15219
        • University of Pittsburgh Medical Center Health System
    • South Carolina
      • Greenville, South Carolina, Stany Zjednoczone, 29601
        • St Francis Hospital
    • Tennessee
      • Knoxville, Tennessee, Stany Zjednoczone, 37909
        • Brig Center for Cancer Care and Survivorship
      • Memphis, Tennessee, Stany Zjednoczone, 38120
        • Baptist Cancer Center
      • Nashville, Tennessee, Stany Zjednoczone, 37201
        • Tennessee Oncology - Skyline Satellite
    • Texas
      • Dallas, Texas, Stany Zjednoczone, 75234
        • BloomTrials Clinical Research, LLC
      • Houston, Texas, Stany Zjednoczone, 77030
        • The Methodist Hospital Research Institute
      • Houston, Texas, Stany Zjednoczone, 77030
        • University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
    • Virginia
      • Fairfax, Virginia, Stany Zjednoczone, 22031
        • Virginia Cancer Specialists
      • Aarau, Szwajcaria, 5000
        • Hirslanden Medical Center
      • Basel, Szwajcaria, 4031
        • Universitaetsspital Basel
      • Chur, Szwajcaria, 7000
        • Kantonsspital Graubuenden
      • Lausanne, Szwajcaria, 1011
        • Centre Hospitalier Universitaire Vaudois
      • Sankt Gallen, Szwajcaria, 9007
        • Kantonsspital St. Gallen
      • Winterthur, Szwajcaria, 8401
        • Kantonsspital Winterthur
      • Zurich, Szwajcaria, 8091
        • Universitaetsspital Zuerich
      • Solna, Szwecja, 17176
        • Karolinska universitetssjukhuset - Solna
      • Sundsvall, Szwecja, 85186
        • Länssjukhuset Sundsvall-Härnösand
      • Uppsala, Szwecja, 75185
        • Akademiska Sjukhuset
      • Kaohsiung City, Tajwan, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Tainan, Tajwan, 704
        • National Cheng Kung University Hospital
      • Taipei, Tajwan, 100
        • National Taiwan University Hospital
      • Budapest, Węgry, 1097
        • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
      • Budapest, Węgry, 1122
        • Orszagos Onkologiai Intezet
      • Debrecen, Węgry, 4032
        • Debreceni Egyetem
      • Gyula, Węgry, 5700
        • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
      • Nyíregyháza, Węgry, 4400
        • SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
      • Szolnok, Węgry, 5004
        • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
      • Bologna, Włochy, 40138
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
      • Brescia, Włochy, 25100
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
      • Catania, Włochy, 95125
        • Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
      • Catanzaro, Włochy, 88100
        • Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
      • Milan, Włochy, 20141
        • IEO Istituto Europeo di Oncologia
      • Naples, Włochy, 80131
        • Istituto Nazionale Tumori Fondazione G. Pascale
      • Rimini, Włochy, 47923
        • Ospedale degli Infermi
      • Roma, Włochy, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Roma, Włochy, 00133
        • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    • Lecce
      • Tricase, Lecce, Włochy, 73039
        • Azienda Ospedaliera Card. G. Panico
    • Milano
      • Monza, Milano, Włochy, 20900
        • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
      • Rozzano, Milano, Włochy, 20089
        • Istituto Clinico Humanitas
    • Verona
      • Negrar, Verona, Włochy, 37024
        • Ospedale Sacro Cuore Don Calabria
    • Cornwall
      • Truro, Cornwall, Zjednoczone Królestwo, TR1 3LJ
        • Royal Cornwall Hospital
    • Greater London
      • London, Greater London, Zjednoczone Królestwo, NW3 2QG
        • Royal Free Hospital
      • London, Greater London, Zjednoczone Królestwo, EC1M 6BQ
        • Queen Mary University of London
      • London, Greater London, Zjednoczone Królestwo, NW1 2PG
        • University College London Hospitals
    • Lothian Region
      • Edinburgh, Lothian Region, Zjednoczone Królestwo, EH4 2XU
        • Western General Hospital
    • Nottinghamshire
      • Nottingham, Nottinghamshire, Zjednoczone Królestwo, NG5 1PB
        • Nottingham University Hospitals City Campus
    • Surrey
      • Guildford, Surrey, Zjednoczone Królestwo, GU2 7XX
        • Royal Surrey County Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Is the age of majority in their country

  • Has pathologically documented breast cancer that:

    1. Is unresectable or metastatic
    2. Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
    3. Is HR-positive or HR-negative
    4. Has progressed on, and would no longer benefit from, endocrine therapy
    5. Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
    6. Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
  • Has documented radiologic progression (during or after most recent treatment)

  • Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:

    1. assessment of HER2 status
    2. assessment of post-treatment status
  • Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1

  • Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions

  • Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)

Exclusion Criteria:

  • Is ineligible for all options in the physician's choice arm
  • Has breast cancer ever assessed with high-HER2 expression
  • Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
  • Has uncontrolled or significant cardiovascular disease
  • Has spinal cord compression or clinically active central nervous system metastases
  • Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Trastuzumab deruxtecan

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a

DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously

Inne nazwy:
  • DS-8201a
Aktywny komparator: Physician's Choice

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:

  • Capecitabine
  • Eribulin
  • Gemcitabine
  • Paclitaxel
  • Nab-paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Ramy czasowe: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Liczba ogólnych zdarzeń związanych z przeżyciem (zgony)
Ramy czasowe: Od daty randomizacji do daty śmierci z jakiejkolwiek przyczyny, do około 3 lat
Od daty randomizacji do daty śmierci z jakiejkolwiek przyczyny, do około 3 lat
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
Ramy czasowe: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Ramy czasowe: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
Ramy czasowe: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Ramy czasowe: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Overall Survival (OS) in All Patients
Ramy czasowe: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Ramy czasowe: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
Ramy czasowe: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Ramy czasowe: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
Ramy czasowe: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
All-Cause Mortality
Ramy czasowe: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Dyrektor Studium: Global Clinical Leader, Daiichi Sankyo

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

27 grudnia 2018

Zakończenie podstawowe (Rzeczywisty)

11 stycznia 2022

Ukończenie studiów (Rzeczywisty)

19 maja 2026

Daty rejestracji na studia

Pierwszy przesłany

6 listopada 2018

Pierwszy przesłany, który spełnia kryteria kontroli jakości

6 listopada 2018

Pierwszy wysłany (Rzeczywisty)

7 listopada 2018

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

28 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

1 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • DS8201-A-U303
  • 2018 (Grant/umowa NIH USA)
  • 2018-003069-33 (Numer EudraCT)
  • 184223 (Identyfikator rejestru: JAPIC CTI)
  • DESTINY-B04 (Inny identyfikator: Daiichi Sankyo and AstraZeneca)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Ramy czasowe udostępniania IPD

Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Kryteria dostępu do udostępniania IPD

Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .